May & Baker Nigeria Valuation
Is MAYBAKER undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MAYBAKER?
Other financial metrics that can be useful for relative valuation.
|What is MAYBAKER's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does MAYBAKER's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
GLAXOSMITH GlaxoSmithKline Consumer Nigeria
FIDSON Fidson Healthcare
524824 Bal Pharma
UPC Universe Pharmaceuticals
MAYBAKER May & Baker Nigeria
Price-To-Earnings vs Peers: MAYBAKER is good value based on its Price-To-Earnings Ratio (4.8x) compared to the peer average (12x).
Price to Earnings Ratio vs Industry
How does MAYBAKER's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?
Price to Earnings Ratio vs Fair Ratio
What is MAYBAKER's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||4.8x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MAYBAKER's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MAYBAKER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MAYBAKER (NGN4.45) is trading above our estimate of fair value (NGN1.93)
Significantly Below Fair Value: MAYBAKER is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.